🇺🇸 FDA

Company profile · Sponsor

Novartis

Novartis Ophthalmics Europe

EB5C22B · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Novartis (EB5C22B) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EB5C22B
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, DOCETAXEL , JDQ443

    Novartis

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  3. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  5. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  6. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  7. ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN

    Novartis

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  8. BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE

    Novartis

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  9. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  10. Bion 1301/FUB523

    Novartis

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  11. CANAKINUMAB, PEMETREXED

    Novartis

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  12. CPI-0610, CPI-0610

    Novartis

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  13. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE

    Novartis

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  15. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  16. EVEROLIMUS

    Novartis

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  17. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  18. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  19. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. INCLISIRAN, -

    Novartis

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  21. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  22. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  23. IPTACOPAN

    Novartis

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  24. IPTACOPAN

    Novartis

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Novartis?

Novartis (EB5C22B) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Novartis sponsor?

We track 24 ClinicalTrials.gov-linked programs for Novartis, including -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, - and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Novartis company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.